| Karl P Undesser, MD | |
|
1906 Fairview Ave Ste 230, Caldwell, ID 83605-5432 | |
| (208) 795-5073 | |
| (208) 402-3181 |
| Full Name | Karl P Undesser |
|---|---|
| Gender | Male |
| Speciality | Cardiac Electrophysiology |
| Experience | 35 Years |
| Location | 1906 Fairview Ave Ste 230, Caldwell, Idaho |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013961242 | NPI | - | NPPES |
| 1013961242 | Medicaid | ID |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0001X | Internal Medicine - Clinical Cardiac Electrophysiology | M6986 (Idaho) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| West Valley Medical Center | Caldwell, ID | Hospital |
| Saint Alphonsus Regional Medical Center | Boise, ID | Hospital |
| St Luke's Regional Medical Center | Boise, ID | Hospital |
| Weiser Memorial Hospital | Weiser, ID | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| West Valley Medical Group Specialty Services Llc | 5799901815 | 10 |
News Archive
ARCA biopharma, Inc. today announced that it has submitted a study protocol for review under the U.S. Food and Drug Administration's (FDA) Special Protocol Assessment (SPA) process for the design of a clinical trial to assess the safety and efficacy of GencaroTM, in approximately 3,000 patients with chronic heart failure who have the genotype that appears to respond most favorably to Gencaro. Gencaro is the Company's investigational, pharmacologically unique beta-blocker and mild vasodilator.
Researchers at Indiana University School of Medicine have taken a step toward understanding the genetics that make people more susceptible to the loss of hearing as they age.
The House Foreign Affairs Committee on Thursday approved legislation (HR 2829) that would withhold up to half of non-voluntary U.S. contributions to the United Nations "if, in two years, the United Nations is not collecting 80 percent of its regular budget in voluntary contributions," Agence France-Presse reports.
Congressional Republicans are pushing an idea unlikely to garner much traction that would force members of Congress who vote for a government-run public plan for health insurance coverage to enroll in it, Politico reports.
Compugen Ltd. announced today the discovery and initial experimental validation of CGEN-928 as a drug target for the treatment of multiple myeloma. In recently completed studies, CGEN-928, a membrane protein which previously had no known function or potential clinical utility, demonstrated broad expression in human multiple myeloma tumor cells, including drug resistant and aggressive primary tumor cell lines.
› Verified 1 days ago
| Entity Name | North Canyon Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609046671 PECOS PAC ID: 0941371439 Enrollment ID: O20090409000304 |
News Archive
ARCA biopharma, Inc. today announced that it has submitted a study protocol for review under the U.S. Food and Drug Administration's (FDA) Special Protocol Assessment (SPA) process for the design of a clinical trial to assess the safety and efficacy of GencaroTM, in approximately 3,000 patients with chronic heart failure who have the genotype that appears to respond most favorably to Gencaro. Gencaro is the Company's investigational, pharmacologically unique beta-blocker and mild vasodilator.
Researchers at Indiana University School of Medicine have taken a step toward understanding the genetics that make people more susceptible to the loss of hearing as they age.
The House Foreign Affairs Committee on Thursday approved legislation (HR 2829) that would withhold up to half of non-voluntary U.S. contributions to the United Nations "if, in two years, the United Nations is not collecting 80 percent of its regular budget in voluntary contributions," Agence France-Presse reports.
Congressional Republicans are pushing an idea unlikely to garner much traction that would force members of Congress who vote for a government-run public plan for health insurance coverage to enroll in it, Politico reports.
Compugen Ltd. announced today the discovery and initial experimental validation of CGEN-928 as a drug target for the treatment of multiple myeloma. In recently completed studies, CGEN-928, a membrane protein which previously had no known function or potential clinical utility, demonstrated broad expression in human multiple myeloma tumor cells, including drug resistant and aggressive primary tumor cell lines.
› Verified 1 days ago
| Entity Name | St Lukes Clinic-treasure Valley Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326336058 PECOS PAC ID: 4981878402 Enrollment ID: O20111119000045 |
News Archive
ARCA biopharma, Inc. today announced that it has submitted a study protocol for review under the U.S. Food and Drug Administration's (FDA) Special Protocol Assessment (SPA) process for the design of a clinical trial to assess the safety and efficacy of GencaroTM, in approximately 3,000 patients with chronic heart failure who have the genotype that appears to respond most favorably to Gencaro. Gencaro is the Company's investigational, pharmacologically unique beta-blocker and mild vasodilator.
Researchers at Indiana University School of Medicine have taken a step toward understanding the genetics that make people more susceptible to the loss of hearing as they age.
The House Foreign Affairs Committee on Thursday approved legislation (HR 2829) that would withhold up to half of non-voluntary U.S. contributions to the United Nations "if, in two years, the United Nations is not collecting 80 percent of its regular budget in voluntary contributions," Agence France-Presse reports.
Congressional Republicans are pushing an idea unlikely to garner much traction that would force members of Congress who vote for a government-run public plan for health insurance coverage to enroll in it, Politico reports.
Compugen Ltd. announced today the discovery and initial experimental validation of CGEN-928 as a drug target for the treatment of multiple myeloma. In recently completed studies, CGEN-928, a membrane protein which previously had no known function or potential clinical utility, demonstrated broad expression in human multiple myeloma tumor cells, including drug resistant and aggressive primary tumor cell lines.
› Verified 1 days ago
| Entity Name | West Valley Medical Group Specialty Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245659093 PECOS PAC ID: 5799901815 Enrollment ID: O20140725002340 |
News Archive
ARCA biopharma, Inc. today announced that it has submitted a study protocol for review under the U.S. Food and Drug Administration's (FDA) Special Protocol Assessment (SPA) process for the design of a clinical trial to assess the safety and efficacy of GencaroTM, in approximately 3,000 patients with chronic heart failure who have the genotype that appears to respond most favorably to Gencaro. Gencaro is the Company's investigational, pharmacologically unique beta-blocker and mild vasodilator.
Researchers at Indiana University School of Medicine have taken a step toward understanding the genetics that make people more susceptible to the loss of hearing as they age.
The House Foreign Affairs Committee on Thursday approved legislation (HR 2829) that would withhold up to half of non-voluntary U.S. contributions to the United Nations "if, in two years, the United Nations is not collecting 80 percent of its regular budget in voluntary contributions," Agence France-Presse reports.
Congressional Republicans are pushing an idea unlikely to garner much traction that would force members of Congress who vote for a government-run public plan for health insurance coverage to enroll in it, Politico reports.
Compugen Ltd. announced today the discovery and initial experimental validation of CGEN-928 as a drug target for the treatment of multiple myeloma. In recently completed studies, CGEN-928, a membrane protein which previously had no known function or potential clinical utility, demonstrated broad expression in human multiple myeloma tumor cells, including drug resistant and aggressive primary tumor cell lines.
› Verified 1 days ago
| Entity Name | Cardiac And Arrhythmia Center Of Idaho Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629707740 PECOS PAC ID: 9032593421 Enrollment ID: O20220902001698 |
News Archive
ARCA biopharma, Inc. today announced that it has submitted a study protocol for review under the U.S. Food and Drug Administration's (FDA) Special Protocol Assessment (SPA) process for the design of a clinical trial to assess the safety and efficacy of GencaroTM, in approximately 3,000 patients with chronic heart failure who have the genotype that appears to respond most favorably to Gencaro. Gencaro is the Company's investigational, pharmacologically unique beta-blocker and mild vasodilator.
Researchers at Indiana University School of Medicine have taken a step toward understanding the genetics that make people more susceptible to the loss of hearing as they age.
The House Foreign Affairs Committee on Thursday approved legislation (HR 2829) that would withhold up to half of non-voluntary U.S. contributions to the United Nations "if, in two years, the United Nations is not collecting 80 percent of its regular budget in voluntary contributions," Agence France-Presse reports.
Congressional Republicans are pushing an idea unlikely to garner much traction that would force members of Congress who vote for a government-run public plan for health insurance coverage to enroll in it, Politico reports.
Compugen Ltd. announced today the discovery and initial experimental validation of CGEN-928 as a drug target for the treatment of multiple myeloma. In recently completed studies, CGEN-928, a membrane protein which previously had no known function or potential clinical utility, demonstrated broad expression in human multiple myeloma tumor cells, including drug resistant and aggressive primary tumor cell lines.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Karl P Undesser, MD Po Box 742941, Atlanta, GA 30374-2941 Ph: () - | Karl P Undesser, MD 1906 Fairview Ave Ste 230, Caldwell, ID 83605-5432 Ph: (208) 795-5073 |
News Archive
ARCA biopharma, Inc. today announced that it has submitted a study protocol for review under the U.S. Food and Drug Administration's (FDA) Special Protocol Assessment (SPA) process for the design of a clinical trial to assess the safety and efficacy of GencaroTM, in approximately 3,000 patients with chronic heart failure who have the genotype that appears to respond most favorably to Gencaro. Gencaro is the Company's investigational, pharmacologically unique beta-blocker and mild vasodilator.
Researchers at Indiana University School of Medicine have taken a step toward understanding the genetics that make people more susceptible to the loss of hearing as they age.
The House Foreign Affairs Committee on Thursday approved legislation (HR 2829) that would withhold up to half of non-voluntary U.S. contributions to the United Nations "if, in two years, the United Nations is not collecting 80 percent of its regular budget in voluntary contributions," Agence France-Presse reports.
Congressional Republicans are pushing an idea unlikely to garner much traction that would force members of Congress who vote for a government-run public plan for health insurance coverage to enroll in it, Politico reports.
Compugen Ltd. announced today the discovery and initial experimental validation of CGEN-928 as a drug target for the treatment of multiple myeloma. In recently completed studies, CGEN-928, a membrane protein which previously had no known function or potential clinical utility, demonstrated broad expression in human multiple myeloma tumor cells, including drug resistant and aggressive primary tumor cell lines.
› Verified 1 days ago
Steven J Koga, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1906 Fairview Ave Ste 230, Caldwell, ID 83605 Phone: 208-459-4667 Fax: 208-459-3372 | |
Dr. Lyndon C Box, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1906 Fairview Ave Ste 230, Caldwell, ID 83605 Phone: 208-459-4667 Fax: 208-442-6520 | |
Nathanael Hogg, D.O Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1717 Arlington Ave, Caldwell, ID 83605 Phone: 808-294-7862 | |
Sherri L Brown, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 315 E Elm St, Caldwell, ID 83605 Phone: 208-459-7415 Fax: 208-453-3200 | |
James C Field, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 315 E Elm St, Ste 350, Caldwell, ID 83605 Phone: 208-454-6363 Fax: 208-454-3512 | |
Dr. Christopher Ryan Keller, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 4620 Enterprise Way Ste 101, Caldwell, ID 83605 Phone: 208-846-8335 Fax: 208-846-8336 |